* This price includes a dispensing fee, medical review fee, and packing fee.
Shipped and delivered directly to your doorstep
Brilinta (active ingredient: ticagrelor) is a prescription medication used to help reduce the risk of serious cardiovascular events caused by blood clots. It is commonly prescribed for people who have experienced certain heart-related conditions, such as a heart attack or acute coronary syndrome.
Brilinta belongs to a class of medications known as antiplatelet agents, specifically P2Y12 platelet inhibitors. It works by preventing blood platelets from sticking together and forming harmful blood clots.
Brilinta is used in combination with aspirin to treat acute coronary syndrome (ACS), a group of conditions caused by a sudden reduction in blood flow to the heart.
These conditions include:
Acute coronary syndrome is a medical emergency that can lead to a heart attack or other serious complications if left untreated.
How Brilinta Helps in ACS
Brilinta is also used in people with a history of myocardial infarction (heart attack) to help prevent future cardiovascular events.
Even after recovery from a heart attack, blood clots can still form and increase the risk of another heart attack, stroke, or cardiovascular death. Long-term treatment with Brilinta can help reduce these risks.
How Brilinta Helps After a Heart Attack
Brilinta contains ticagrelor, which blocks a receptor on platelets called the P2Y12 receptor.
Platelets are blood cells that help stop bleeding by forming clots. In some cardiovascular conditions, platelets can become overactive and form unwanted blood clots inside blood vessels.
By blocking platelet activation and aggregation, Brilinta helps:
Because Brilinta affects the blood’s ability to clot, it is important to take the medication exactly as prescribed and attend regular follow-up appointments with your healthcare provider.
Brilinta is available as an oral tablet and should be taken exactly as prescribed by your healthcare provider.
The tablets may be taken with or without food. If you have difficulty swallowing tablets, Brilinta tablets can be crushed and mixed with water for immediate consumption. In certain situations, the medication may also be administered through a nasogastric tube, as directed by a healthcare professional.
For patients with acute coronary syndrome (ACS), treatment is typically started with a:
This is followed by:
After one year of treatment, the dose is usually reduced to:
For certain patients with coronary artery disease (CAD), the recommended dose is:
Brilinta is often prescribed together with a daily maintenance dose of aspirin (75 mg to 100 mg once daily), unless your healthcare provider recommends otherwise.
If you have kidney problems or other medical conditions, your healthcare provider will determine the most appropriate treatment plan and monitor you as needed.
Regular follow-up appointments are important to help ensure Brilinta continues to provide effective protection against blood clots and cardiovascular complications.
Brilinta and its generic alternative Ticagrelor are available in the following forms and strengths:
Brilinta works by blocking platelet activation and preventing blood clots from forming. It does this by inhibiting the P2Y12 receptor, a key component involved in platelet aggregation.
Because Brilinta reduces the blood’s ability to clot, it can increase the risk of bleeding. Bleeding may occur more easily and may take longer than usual to stop.
The risk of bleeding may be higher in people with certain medical conditions, including:
Before starting Brilinta, discuss your medical history with your healthcare provider so they can determine whether the benefits of treatment outweigh the potential risks.
Brilinta is often prescribed together with aspirin. However, taking maintenance doses of aspirin greater than 100 mg daily may reduce the effectiveness of Brilinta.
After the initial aspirin loading dose, most patients should take a maintenance aspirin dose of:
Always follow your healthcare provider’s instructions regarding aspirin use while taking Brilinta.
Some people may develop shortness of breath while taking Brilinta.
Contact your healthcare provider if you experience:
In many cases, mild to moderate shortness of breath does not require treatment and may improve over time. If symptoms become severe or difficult to tolerate, your healthcare provider may evaluate whether an alternative antiplatelet medication is appropriate.
Do not stop taking Brilinta unless your healthcare provider instructs you to do so.
Stopping Brilinta prematurely can significantly increase the risk of:
If Brilinta must be temporarily stopped for surgery, a medical procedure, or another reason, your healthcare provider will advise you when to restart treatment. In most cases, Brilinta should be restarted as soon as it is safe to do so.
Regular follow-up appointments can help your healthcare provider monitor for bleeding, assess side effects, and ensure Brilinta continues to provide effective protection against cardiovascular events.
Brilinta should not be used by people with active bleeding, such as bleeding from the stomach, intestines, or other areas of the body, a history of intracranial hemorrhage (bleeding in the brain), or severe liver impairment. Because Brilinta reduces the blood’s ability to clot, it may increase the risk of serious or potentially life-threatening bleeding in these individuals. Before starting treatment, your healthcare provider will review your medical history and determine whether Brilinta is a safe and appropriate option for you.
Brilinta is often prescribed together with low-dose aspirin to help reduce the risk of blood clots that can lead to heart attacks or strokes. Using Brilinta and aspirin together is known as dual antiplatelet therapy (DAPT). This combination works by preventing platelets from sticking together and forming harmful blood clots. It is important not to stop taking Brilinta or aspirin without first speaking with your healthcare provider, as stopping either medication too soon may increase your risk of a heart attack, stroke, blood clot formation, or cardiovascular death.
Brilinta is typically used as a long-term treatment. The recommended duration depends on your medical condition, risk factors, and response to therapy. For many patients, treatment continues for at least 6 to 12 months following an acute coronary syndrome event. Some patients may benefit from longer treatment based on their healthcare provider’s assessment. Your healthcare provider will determine how long you should continue taking Brilinta.
Yes. Brilinta can be taken in the morning and evening, provided that doses are taken approximately 12 hours apart. Many patients take one dose in the morning and one dose in the evening as part of their prescribed treatment schedule. To help maintain consistent medication levels in your body and maximize treatment effectiveness, try to take Brilinta at the same times each day.
| Generic name: | Ticagrelor |
|---|---|
| Formulation: | Tablet |
| Strength(s): | 60mg, 90mg |
| Quantities Available: | 56, 84, 100, 168 |
Our online Canadian Pharmacy is known for high standards of quality, safety, and efficiency when it comes to medications.
Our pharmacy offers lower prices on prescription drugs compared to traditional pharmacies.
When ordering Brilinta (ticagrelor) from a Canadian pharmacy, you can typically purchase up to a 90-day supply at one time, which is standard for prescription medications to ensure continuous treatment without frequent refills.
Here’s what you need to know:
Dosage and Quantity: Brilinta is commonly prescribed in dosages of 90 mg and 60 mg, taken twice daily. For a 90-day supply, you would order 180 tablets (90 days x 2 tablets per day).
Yes, we do sell ticagrelor on our website. You can enjoy low prices for this medication. However, please note that you will need a valid prescription from your healthcare provider in order to purchase ticagrelor from us. We require this prescription to dispense the medication safely and legally. You can conveniently provide your prescription by mailing, faxing, or uploading it through your online account on our website.
Yes, we ship Brilinta (ticagrelor) to both the United States and Puerto Rico.
Online Pharmacies Canada has provided information from third parties intended to increase awareness and does not contain all the information about Brilinta (Ticagrelor). Talk to your doctor or other qualified medical practitioners for medical attention or advice, or if you have any concerns about Brilinta (Ticagrelor).
REVIEWS